Blog
RSS FeedPosted by Michael Wonder on 01 Apr 2019
Assessing data sources for medicine price studies
29 March 2019 - There is no established methodology to assess the feasibility of medicine price data sources. ...
Posted by Michael Wonder on 18 Mar 2019
CMA drops anti-competitive case against MSD
18 March 2019 - The Competition and Markets Authority has closed its investigation into a suspected anti-competitive discount scheme developed ...
Posted by Michael Wonder on 12 Mar 2019
Optimism on Orkambi in England as talks to resume
12 March 2019 - Scotland's deal puts pressure on NHS England and NICE. ...
Posted by Michael Wonder on 08 Mar 2019
High price of cystic fibrosis drug not political, firm's boss tells MPs
8 March 2019 - CEO of company that makes Orkambi denies being ‘political minion’ for Donald Trump. ...
Posted by Michael Wonder on 05 Mar 2019
How to fix a problem like Orkambi? Solutions suggested ahead of showdown
5 March 2019 - Approaches used in France and Germany could help break deadlock. ...
Posted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 12 Feb 2019
Cystic fibrosis scandal: fury over US firm's 'refusal' to set price for life-saving drugs
11 February 2019 - A US drugs firm is "playing with people's lives" by refusing to do a deal over Orkambi, ...
Posted by Michael Wonder on 31 Jan 2019
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
31 January 2019 - Members of parliament aim to break three year deadlock. ...
Posted by Michael Wonder on 28 Jan 2019
Cystic fibrosis patients lobby Vertex to drop drug prices
28 January 2019 - Healthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to ...
Posted by Michael Wonder on 21 Jan 2019
New agreement on branded drugs for the NHS
18 January 2019 - The new Voluntary Scheme for Branded Medicines Pricing and Access began on 1 January and was ...
Posted by Michael Wonder on 16 Jan 2019
The UK’s new five year pricing agreement
16 January 2019 - Pharma has agreed to capped growth again – in exchange for uptake promises. ...
Posted by Michael Wonder on 20 Dec 2018
Warning of rising drug prices as Britain prepares for no-deal Brexit
20 December 2018 - It comes as it was revealed that Matt Hancock has chartered a plane to airlift supplies. ...
Posted by Michael Wonder on 13 Dec 2018
Brexit contributes to surge in generic drug prices
13 December 2018 - Calls for government to protect pharmacies. ...
Posted by Michael Wonder on 27 Nov 2018
Pharma agrees to 2 percent cap on branded meds growth
25 November 2018 - The Association of the British Pharmaceutical Industry has agreed the terms of the 2019 Pharmaceutical Price ...
Posted by Michael Wonder on 23 Nov 2018
Multi-indication pricing: nice in theory but can it work in practice?
24 November 2018 - For medicines with different valued indications, multi-indication pricing implies charging different prices for different uses. ...